PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a single centre non-randomised open label phase 1 trial of lung SBRT to part of a
lung lesion in patients with advanced NSCLC in combination with pembrolizumab. This study
will recruit up to 24 patients whose lung cancer has progressed beyond one line of palliative
chemotherapy, and an EGFR or ALK inhibitor if an EGFR driver mutation or ALK gene
rearrangement is present, respectively, and now requires further palliative systemic
treatment.